SCHEMBL5744780

SCHEMBL5744780

CCN1c2ncc(CCOc3ccnc4ccccc34)cc2C(=O)N(C)c2ccc(F)nc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 5/20 0.64
CYP3A4 P08684 4/20 0.64
CYP2C19 P33261 4/20 0.64
CYP1A2 P05177 3/20 0.64
CYP2D6 P10635 1/20 0.34
DCLK1 O15075 1/20 0.32
MAPK7 Q13164 1/20 0.32
LRRK2 Q5S007 1/20 0.32
PDE10A Q9Y233 2/20 0.32
HTR1A P08908 2/20 0.31
MET P08581 3/20 0.31
KCNA5 P22460 1/20 0.31
KCNJ5 P48544 1/20 0.31
KCNJ3 P48549 1/20 0.31
HTR1D P28221 1/20 0.30
HTR1B P28222 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HSD17B10 Q99714 1/20 0.30
BRD4 O60885 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742832 0.91 CYP2C9 (0.54) CYP2C9CYP3A4CYP2C19CYP1A2CYP2D6
SCHEMBL5745565 0.90 CYP2C9 (0.52) CYP2C9CYP3A4CYP2C19CYP1A2CYP2D6
SCHEMBL5779285 0.90 CYP3A4 (0.52) CYP2C9CYP3A4CYP2C19CYP1A2DCLK1
SCHEMBL5244757 0.88 CYP3A4 (0.65) CYP2C9CYP3A4CYP2C19CYP1A2PDE10A
Hydrochloric Acid SCHEMBL5243727 0.87 CYP3A4 (0.64) CYP2C9CYP3A4CYP2C19CYP1A2PDE10A
Ether SCHEMBL5358570 0.85 CYP3A4 (0.61) CYP2C9CYP3A4CYP2C19CYP1A2PDE10A
SCHEMBL5743230 0.85 CYP3A4 (0.61) CYP2C9CYP3A4CYP2C19CYP1A2CYP2D6
SCHEMBL14383886 0.84 CYP2C9 (0.66) CYP2C9CYP3A4CYP2C19CYP1A2PDE10A
SCHEMBL5745445 0.83 CYP3A4 (0.61) CYP2C9CYP3A4CYP2C19CYP1A2CYP2D6
SCHEMBL6954771 0.82 CYP3A4 (0.66) CYP2C9CYP3A4CYP2C19CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655300-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2006-05-10 EP disclosed
EP-1294720-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM CA LTD (CA) 2006-04-05 EP disclosed
US-6420359-B1 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-07-16 US disclosed
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors REV1, POLR2H, POLR2E CYP2C9 1933/4885CYP3A4 560/4885CYP2C19 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.